396 results on '"Bagel, Jerry"'
Search Results
2. Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b study
3. Tapinarof cream 1% once daily for the treatment of plaque psoriasis: Patient-reported outcomes from the PSOARING 3 trial
4. Outcomes of Biologic Use in Asian Compared with Non-Hispanic White Adult Psoriasis Patients from the CorEvitas Psoriasis Registry
5. Psoriasis improvements and inflammatory biomarker normalization with secukinumab: the randomized ObePso-S study
6. Baseline Demographics and Severity and Burden of Atopic Dermatitis in Adult Patients Initiating Dupilumab Treatment in a Real-World Registry (PROSE)
7. Apremilast
8. Deucravacitinib Long-Term Efficacy in Week 16 Placebo Crossovers: 3-year Results from the POETYK PSO Program
9. Tralokinumab does not impact vaccine-induced immune responses: Results from a 30-week, randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis
10. Impact of psoriasis disease severity and special area involvement on patient-reported outcomes in the real world: an analysis from the CorEvitas psoriasis registry.
11. 508 - Dupilumab treatment normalizes intraepidermal nerve fiber density in patients with moderate-to-severe AD
12. 557 - Tralokinumab real-world use in adults with atopic dermatitis: baseline characteristics of the first 100 patients recruited to the TRACE study in the United States
13. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris – A randomized phase II study
14. Impact of psoriasis disease severity and special area involvement on patient-reported outcomes in the real world: an analysis from the CorEvitas psoriasis registry
15. Adjunctive Use of Calcipotriene/Betamethasone Dipropionate Foam in a Real-World Setting Curtails the Cost of Biologics Without Reducing Efficacy in Psoriasis
16. Treatment of Medicare Patients with Moderate-to-Severe Psoriasis who Cannot Afford Biologics or Apremilast
17. Efficacy and Safety of Risankizumab Compared with Apremilast in Patients with Moderate Plaque Psoriasis: Mean PASI and BSA Results From the Phase 4 IMMpulse Trial
18. Apremilast
19. Transitioning Biologic and Systemic Therapies in Psoriatic Patients
20. Biosimilars for Immune-Mediated Chronic Diseases in Primary Care: What a Practicing Physician Needs to Know
21. Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)
22. Enthesitis and Dactylitis in Psoriatic Disease: A Guide for Dermatologists
23. Real-world evidence on atopic dermatitis: Baseline characteristics and predictors of treatment choice in the TARGET cohort
24. Tildrakizumab in Combination With Topical Halcinonide 0.1% Ointment for Treating Moderate to Severe Plaque Psoriasis
25. Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summary
26. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: efficacy by baseline body surface area (BSA) involvement and baseline Psoriasis Area and Severity Index (PASI)
27. Halobetasol Propionate 0.01% Lotion for Plaque Psoriasis: Epidermal Permeation, Efficacy, and Safety
28. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial
29. Deucravacitinib in plaque psoriasis: 2-year laboratory results from the phase 3 POETYK PSO program
30. T-Cell Targeted Therapy: Alefacept and Efalizumab
31. Serious infections in patients with self-reported psoriatic arthritis from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) treated with biologics
32. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial
33. Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial
34. Outcomes of Biologic Use in Asian Compared with Non-Hispanic White Adult Psoriasis Patients from the CorEvitas Psoriasis Registry
35. Deucravacitinib in plaque psoriasis: 2-year laboratory results from the phase 3 POETYK PSO program
36. Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis
37. 33463 Pooled efficacy and safety results from the DERMIS-1 and DERMIS-2 phase 3 trials of once-daily roflumilast cream 0.3% by baseline body surface area
38. 34613 Tapinarof cream 1% once daily (QD) for plaque psoriasis: Secondary efficacy outcomes from a long-term extension (LTE) trial
39. 34313 Improvement in disease severity and quality of life in patients with atopic dermatitis (AD) treated with dupilumab for up to 18 months: Real-world evidence from the PROSE registry
40. 53817 Patient-reported outcomes with roflumilast foam 0.3% in patients with scalp and body psoriasis in the phase 3 ARRECTOR trial
41. 52826 Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: Week 52 results of a multicenter, randomized, double-blind, placebo-controlled clinical study
42. 52244 Early Improvement in Nail and Scalp Psoriasis from a Prospective Observational Study of Patients with Psoriasis in Special Areas (PSoSA) Initiating Ixekizumab: Results from the First Interim Analysis
43. 50250 Comparing the Effect of Risankizumab versus Apremilast on Psoriasis Symptoms, Treatment Satisfaction, and Health-Related Quality of Life from the Phase 4 IMMpulse Study
44. 54131 Malignancy Rates in Patients With a History of Malignancy in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
45. Transitioning Biologic and Systemic Therapies in Psoriatic Patients
46. The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study
47. From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis
48. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial*
49. Patient Satisfaction with Tapinarof Cream 1% Once Daily for Plaque Psoriasis in a Long-Term Extension Trial
50. Definitions of Measures of Effect Duration for Psoriasis Treatments
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.